Key terms
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest APLS news
Today
11:45am ET
Buy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth Potential
Today
3:08am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX) and Healthcare Services (HCSG)
Today
2:24am ET
Impact of Izervay’s Growth on Apellis Pharmaceuticals: Maintaining a Hold Rating Amidst Rising Competition
Yesterday
10:15am ET
Maintaining Market Dominance: Strong Buy Rating on Apellis Pharmaceuticals with a Target Price of $85
Apr 18
6:45am ET
Wells Fargo Remains a Hold on Apellis Pharmaceuticals (APLS)
Apr 18
1:10am ET
Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)
Apr 15
6:20am ET
Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Rewalk Robotics (LFWD) and Apellis Pharmaceuticals (APLS)
Apr 09
6:40am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)
Mar 29
4:30am ET
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Apellis Pharmaceuticals (APLS)
Mar 29
4:20am ET
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Bluebird Bio (BLUE)
Mar 19
7:10am ET
Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Apellis Pharmaceuticals (APLS) and Ultragenyx Pharmaceutical (RARE)
Mar 11
7:09am ET
Apellis appoints Philip Ferrone as chief medical retina advisor
Mar 07
12:00am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Laboratory (LH), Apellis Pharmaceuticals (APLS) and Iovance Biotherapeutics (IOVA)
Mar 04
7:10am ET
EyePoint appoints Ribeiro as Chief Medical Officer
Mar 04
6:27am ET
Apellis price target raised to $89 from $87 at UBS
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
8:44am ET
Apellis price target raised to $67 from $60 at Wedbush
Feb 28
7:40am ET
Apellis price target raised to $84 from $77 at BofA
Feb 28
6:55am ET
Apellis price target raised to $100 from $81 at Baird
Feb 28
6:36am ET
Buy Rating Affirmed for Apellis Pharmaceuticals Amid Strong Syfovre Performance and Expanding Market Opportunities
Feb 28
5:48am ET
Buy Rating Affirmed for Apellis Pharmaceuticals Amid Strong Syfovre Sales and Expanding Market Potential
Feb 28
12:05am ET
Maintaining Hold on Apellis Pharmaceuticals Amid Syfovre’s Uncertain EMA Approval Prospects
Feb 27
1:15pm ET
Strong Syfovre Sales Drive Buy Recommendation for Apellis Pharmaceuticals with Revised $85 Price Target
Feb 27
1:00pm ET
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Denali Therapeutics (DNLI)
Feb 27
7:09am ET
Apellis expects cash to fund expenditures for ‘foreseeable future’
Feb 27
7:08am ET
Apellis reports Q4 EPS (73c), consensus (69c)
Feb 15
6:46am ET
Apellis price target raised to $60 from $49 at Mizuho
Feb 07
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Feb 07
8:38am ET
Apellis Pharmaceuticals Outperforms Astellas: A Strong Buy Recommendation
Feb 05
11:25am ET
Apellis price target raised to $110 from $106 at Raymond James
No recent press releases are available for APLS
APLS Financials
Key terms
Ad Feedback
APLS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
APLS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
